Dr  Alexandra Brown

Dr Alexandra Brown

Post Doctorate Researcher

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Brown is an early career researcher and respiratory immunologist at the Priority Research Centre for Healthy Lungs at The University of Newcastle (UoN) and the Immune Health Program at the Hunter Medical Research Institute (HMRI). Dr Brown's research focuses on investigating high burden respiratory diseases, particularly the interactions between bacterial and viral respiratory infections with host immune responses in asthmatic disease, aiming to create a greater understanding of the pathogenesis of respiratory disease to discover novel therapeutic targets.

Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Respiratory Disease

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
320103 Respiratory diseases 40
320499 Immunology not elsewhere classified 30
320211 Infectious diseases 30

Professional Experience

UON Appointment

Title Organisation / Department
Post Doctorate Researcher University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Awards

Award

Year Award
2016 ICI Travel Award
Australasian Society for Immunology

Recipient

Year Award
2019 Faculty of Health and Medicine Research Travel Grant Scheme
Faculty of Health and Medicine, The University of Newcastle
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (29 outputs)

Year Citation Altmetrics Link
2024 Mayall JR, Horvat JC, Mangan NE, Chevalier A, McCarthy H, Hampsey D, et al., 'Interferon-epsilon is a novel regulator of NK cell responses in the uterus', EMBO Molecular Medicine, 16 267-293 [C1]
DOI 10.1038/s44321-023-00018-6
Co-authors Chantal Donovan, Bridie Goggins, Jay Horvat, Jemma Mayall, Pradeep Tanwar, Steven Maltby, Simon Keely
2023 Tu X, Gomez HM, Kim RY, Brown AC, de Jong E, Galvao I, et al., 'Airway and parenchyma transcriptomics in a house dust mite model of experimental asthma', Respiratory Research, 24 (2023) [C1]

Lung transcriptomics studies in asthma have provided valuable information in the whole lung context, however, deciphering the individual contributions of the airway and parenchyma... [more]

Lung transcriptomics studies in asthma have provided valuable information in the whole lung context, however, deciphering the individual contributions of the airway and parenchyma in disease pathogenesis may expedite the development of novel targeted treatment strategies. In this study, we performed transcriptomics on the airway and parenchyma using a house dust mite (HDM)-induced model of experimental asthma that replicates key features of the human disease. HDM exposure increased the expression of 3,255 genes, of which 212 were uniquely increased in the airways, 856 uniquely increased in the parenchyma, and 2187 commonly increased in both compartments. Further interrogation of these genes using a combination of network and transcription factor enrichment analyses identified several transcription factors that regulate airway and/or parenchymal gene expression, including transcription factor EC (TFEC), transcription factor PU.1 (SPI1), H2.0-like homeobox (HLX), metal response element binding transcription factor-1 (MTF1) and E74-like factor 4 (ets domain transcription factor, ELF4) involved in controlling innate immune responses. We next assessed the effects of inhibiting lung SPI1 responses using commercially available DB1976 and DB2313 on key disease outcomes. We found that both compounds had no protective effects on airway inflammation, however DB2313 (8¿mg/kg) decreased mucus secreting cell number, and both DB2313 (1¿mg/kg) and DB1976 (2.5¿mg/kg and 1¿mg/kg) reduced small airway collagen deposition. Significantly, both compounds decreased airway hyperresponsiveness. This study demonstrates that SPI1 is important in HDM-induced experimental asthma and that its pharmacological inhibition reduces HDM-induced airway collagen deposition and hyperresponsiveness.

DOI 10.1186/s12931-022-02298-x
Co-authors Henry Gomez, Jay Horvat, Chantal Donovan
2023 Carroll OR, Pillar AL, Brown AC, Feng M, Chen H, Donovan C, 'Advances in respiratory physiology in mouse models of experimental asthma.', Front Physiol, 14 1099719 (2023) [C1]
DOI 10.3389/fphys.2023.1099719
Citations Scopus - 5
Co-authors Chantal Donovan
2023 Horvat JC, Kim RY, Weaver N, Augood C, Brown AC, Donovan C, et al., 'Characterization and inhibition of inflammasome responses in severe and non-severe asthma.', Respir Res, 24 303 (2023) [C1]
DOI 10.1186/s12931-023-02603-2
Co-authors Jemma Mayall, Chantal Donovan, Jay Horvat, Natasha Weaver, Liz Holliday
2023 Scott HA, Ng SH, McLoughlin RF, Valkenborghs SR, Nair P, Brown AC, et al., 'Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis.', Thorax, 78 957-965 (2023) [C1]
DOI 10.1136/thorax-2022-219268
Citations Scopus - 3
Co-authors Sarah Valkenborghs, Jay Horvat, Hayley Scott, Lisa Wood
2022 Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, et al., 'Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages', Cell Metabolism, 34 487-501.e8 (2022) [C1]

The Krebs cycle-derived metabolite itaconate and its derivatives suppress the inflammatory response in pro-inflammatory ¿M1¿ macrophages. However, alternatively activated ¿M2¿ mac... [more]

The Krebs cycle-derived metabolite itaconate and its derivatives suppress the inflammatory response in pro-inflammatory ¿M1¿ macrophages. However, alternatively activated ¿M2¿ macrophages can take up itaconate. We therefore examined the effect of itaconate and 4-octyl itaconate (OI) on M2 macrophage activation. We demonstrate that itaconate and OI inhibit M2 polarization and metabolic remodeling. Examination of IL-4 signaling revealed inhibition of JAK1 and STAT6 phosphorylation by both itaconate and OI. JAK1 activation was also inhibited by OI in response to IL-13, interferon-ß, and interferon-¿ in macrophages and in T helper 2 (Th2) cells. Importantly, JAK1 was directly modified by itaconate derivatives at multiple residues, including cysteines 715, 816, 943, and 1130. Itaconate and OI also inhibited JAK1 kinase activity. Finally, OI treatment suppressed M2 macrophage polarization and JAK1 phosphorylation in vivo. We therefore identify itaconate and OI as JAK1 inhibitors, suggesting a new strategy to inhibit JAK1 in M2 macrophage-driven diseases.

DOI 10.1016/j.cmet.2022.02.002
Citations Scopus - 108Web of Science - 40
Co-authors Jay Horvat
2022 Pinkerton JW, Kim RY, Brown AC, Rae BE, Donovan C, Mayall JR, et al., 'Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 149 1270-1280 (2022) [C1]
DOI 10.1016/j.jaci.2021.10.003
Citations Scopus - 21Web of Science - 7
Co-authors Jemma Mayall, Jay Horvat, Lisa Wood, Chantal Donovan, Bronwyn Berthon, Katherine Baines, Hayley Scott
2022 Donovan C, Kim RY, Galvao I, Jarnicki AG, Brown AC, Jones-Freeman B, et al., 'Aim2 suppresses cigarette smoke-induced neutrophil recruitment, neutrophil caspase-1 activation and anti-Ly6G-mediated neutrophil depletion', IMMUNOLOGY AND CELL BIOLOGY, 100 235-249 (2022) [C1]
DOI 10.1111/imcb.12537
Citations Scopus - 6Web of Science - 5
Co-authors Chantal Donovan, Kurtis Budden, Jemma Mayall, Jay Horvat, Henry Gomez
2022 Pathinayake PS, Waters DW, Nichol KS, Brown AC, Reid AT, Hsu AC-Y, et al., 'Endoplasmic reticulum-unfolded protein response signalling is altered in severe eosinophilic and neutrophilic asthma', THORAX, 77 443-451 (2022) [C1]
DOI 10.1136/thoraxjnl-2020-215979
Citations Scopus - 18Web of Science - 12
Co-authors Prabuddha Pathinayake, Jay Horvat, Lisa Wood, Katherine Baines, Jodie Simpson, Andrew Reid
2022 Ren S, Hansbro PM, Srikusalanukul W, Horvat JC, Hunter T, Brown AC, et al., 'Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial', Atherosclerosis, 346 68-74 (2022) [C1]

Background and aims: Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may ... [more]

Background and aims: Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE) is a double-blind, randomised controlled trial (RCT) of PPV in preventing ischaemic events. Participants received PPV or placebo once at baseline and are being followed-up for incident fatal and non-fatal myocardial infarction or stroke over 6 years. Methods: A subgroup of participants at one centre (Canberra; n = 1,001) were evaluated at 1 month and 2 years post immunisation for changes in surrogate markers of atherosclerosis, as pre-specified secondary outcomes: high-sensitive C-reactive protein (CRP), pulse wave velocity (PWV), and carotid intima-media thickness (CIMT). In addition, 100 participants were randomly selected in each of the intervention and control groups for measurement of anti-pneumococcal antibodies (IgG, IgG2, IgM) as well as anti-OxLDL antibodies (IgG and IgM to CuOxLDL, MDA-LDL, and PC-KLH). Results: Concentrations of anti-pneumococcal IgG and IgG2 increased and remained high at 2 years in the PPV group compared to the placebo group, while IgM increased and then declined, but remained detectable, at 2 years. There were statistically significant increases in all anti-OxLDL IgM antibodies at 1 month, which were no longer detectable at 2 years; there was no increase in anti-OxLDL IgG antibodies. There were no significant changes in CRP, PWV or CIMT between the treatment groups at the 2-year follow-up. Conclusions: PPV engenders a long-lasting increase in anti-pneumococcal IgG, and to a lesser extent, IgM titres, as well as a transient increase in anti-OxLDL IgM antibodies. However, there were no detectable changes in surrogate markers of atherosclerosis at the 2-year follow-up. Long-term, prospective follow-up of clinical outcomes is continuing to assess if PPV reduces CVD events.

DOI 10.1016/j.atherosclerosis.2022.02.011
Citations Scopus - 8
Co-authors Christopher Levi, David Newby, Mark Mcevoy, Alexis Hure, John Attia, Jay Horvat, Shuchuen Li, Catherine Deste, David Durrheim
2022 Tu X, Kim RY, Brown AC, de Jong E, Jones-Freeman B, Ali MK, et al., 'Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap', Journal of Allergy and Clinical Immunology, 150 817-829.e6 (2022) [C1]

Background: Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COP... [more]

Background: Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COPD overlap (ACO). Patients characterized with ACO have increased disease severity; however, the mechanisms driving this have not been widely studied. Objectives: This study sought to characterize the phenotypic and transcriptomic features of experimental ACO in mice induced by chronic house dust mite antigen and cigarette smoke exposure. Methods: Female BALB/c mice were chronically exposed to house dust mite antigen for 11 weeks to induce experimental asthma, cigarette smoke for 8 weeks to induce experimental COPD, or both concurrently to induce experimental ACO. Lung inflammation, structural changes, and lung function were assessed. RNA-sequencing was performed on separated airway and parenchyma lung tissues to assess transcriptional changes. Validation of a novel upstream driver SPI1 in experimental ACO was assessed using the pharmacological SPI1 inhibitor, DB2313. Results: Experimental ACO recapitulated features of both asthma and COPD, with mixed pulmonary eosinophilic/neutrophilic inflammation, small airway collagen deposition, and increased airway hyperresponsiveness. Transcriptomic analysis identified common and distinct dysregulated gene clusters in airway and parenchyma samples in experimental asthma, COPD, and ACO. Upstream driver analysis revealed increased expression of the transcription factor Spi1. Pharmacological inhibition of SPI1 using DB2313, reduced airway remodeling and airway hyperresponsiveness in experimental ACO. Conclusions: A new experimental model of ACO featuring chronic dual exposures to house dust mite and cigarette smoke mimics key disease features observed in patients with ACO and revealed novel disease mechanisms, including upregulation of SPI1, that are amenable to therapy.

DOI 10.1016/j.jaci.2022.04.032
Citations Scopus - 7Web of Science - 2
Co-authors Kurtis Budden, Guy Cameron, Henry Gomez, Tattjhong Haw, Chantal Donovan, Jay Horvat
2021 La T, Chen S, Guo T, Zhao XH, Teng L, Li D, et al., 'Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells', THERANOSTICS, 11 9605-9622 (2021) [C1]
DOI 10.7150/thno.63763
Citations Scopus - 12Web of Science - 9
Co-authors Xiaohong Zhao, Lei Jin, Xu Zhang, Yuanyuan Zhang
2021 Brown AC, Horvat JC, 'Casting Iron in the Pathogenesis of Fibrotic Lung Disease', AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 65 130-131 (2021)
DOI 10.1165/rcmb.2021-0135ED
Citations Scopus - 2Web of Science - 1
Co-authors Jay Horvat
2021 Pinkerton JW, Kim RY, Koeninger L, Armbruster NS, Hansbro NG, Brown AC, et al., 'Human ß-defensin-2 suppresses key features of asthma in murine models of allergic airways disease', CLINICAL AND EXPERIMENTAL ALLERGY, 51 120-131 (2021) [C1]
DOI 10.1111/cea.13766
Citations Scopus - 20Web of Science - 10
Co-authors Jay Horvat
2021 Gomez HM, Pillar AL, Brown AC, Kim RY, Ali MK, Essilfie A-T, et al., 'Investigating the Links between Lower Iron Status in Pregnancy and Respiratory Disease in Offspring Using Murine Models', NUTRIENTS, 13 (2021) [C1]
DOI 10.3390/nu13124461
Citations Scopus - 2
Co-authors Rebecca Vanders, Vanessa Murphy, Henry Gomez, Liz Milward, Adam Collison, Megan Jensen, Daniel Johnstone, Chantal Donovan, Jay Horvat
2020 Vidaillac C, Yong VFL, Aschtgen MS, Qu J, Yang S, Xu G, et al., 'Sex steroids induce membrane stress responses and virulence properties in pseudomonas aeruginosa', mBio, 11 1-19 (2020) [C1]

Estrogen, a major female sex steroid hormone, has been shown to promote the selection of mucoid Pseudomonas aeruginosa in the airways of patients with chronic respiratory diseases... [more]

Estrogen, a major female sex steroid hormone, has been shown to promote the selection of mucoid Pseudomonas aeruginosa in the airways of patients with chronic respiratory diseases, including cystic fibrosis. This results in long-term persistence, poorer clinical outcomes, and limited therapeutic options. In this study, we demonstrate that at physiological concentrations, sex steroids, including testosterone and estriol, induce membrane stress responses in P. aeruginosa. This is characterized by increased virulence and consequent inflammation and release of proinflammatory outer membrane vesicles promoting in vivo persistence of the bacteria. The steroid-induced P. aeruginosa response correlates with the molecular polarity of the hormones and membrane fluidic properties of the bacteria. This novel mechanism of interaction between sex steroids and P. aeruginosa explicates the reported increased disease severity observed in females with cystic fibrosis and provides evidence for the therapeutic potential of the modulation of sex steroids to achieve better clinical outcomes in patients with hormone-responsive strains. IMPORTANCE Molecular mechanisms by which sex steroids interact with P. aeruginosa to modulate its virulence have yet to be reported. Our work provides the first characterization of a steroid-induced membrane stress mechanism promoting P. aeruginosa virulence, which includes the release of proinflammatory outer membrane vesicles, resulting in inflammation, host tissue damage, and reduced bacterial clearance. We further demonstrate that at nanomolar (physiological) concentrations, male and female sex steroids promote virulence in clinical strains of P. aeruginosa based on their dynamic membrane fluidic properties. This work provides, for the first-time, mechanistic insight to better understand and predict the P. aeruginosa related response to sex steroids and explain the interindividual patient variability observed in respiratory diseases such as cystic fibrosis that are complicated by gender differences and chronic P. aeruginosa infection.

DOI 10.1128/mBio.01774-20.
Citations Scopus - 15Web of Science - 16
Co-authors Jay Horvat
2020 Marshall RJ, Armart P, Hulme KD, Chew KY, Brown AC, Hansbro PM, et al., 'Glycemic Variability in Diabetes Increases the Severity of Influenza', MBIO, 11 [C1]
DOI 10.1128/mBio.02841-19
Citations Scopus - 32Web of Science - 21
2020 Ali MK, Kim RY, Brown AC, Donovan C, Vanka KS, Mayall JR, et al., 'Critical role for iron accumulation in the pathogenesis of fibrotic lung disease', JOURNAL OF PATHOLOGY, 251 49-62 (2020) [C1]
DOI 10.1002/path.5401
Citations Scopus - 66Web of Science - 57
Co-authors Jay Horvat, Jemma Mayall, Daniel Johnstone, Liz Milward, Chantal Donovan
2020 Ali MK, Kim RY, Brown AC, Mayall JR, Karim R, Pinkerton JW, et al., 'Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma', EUROPEAN RESPIRATORY JOURNAL, 55 (2020) [C1]
DOI 10.1183/13993003.01340-2019
Citations Scopus - 42Web of Science - 36
Co-authors Liz Milward, Daniel Johnstone, Liz Holliday, Prabuddha Pathinayake, Chantal Donovan, Jemma Mayall, Jay Horvat
2020 Vidaillac C, Yong VFL, Aschtgen M-S, Qu J, Yang S, Xu G, et al., 'Sex Steroids Induce Membrane Stress Responses and Virulence Properties in Pseudomonas aeruginosa (vol 11, e01774-20, 2020)', MBIO, 11 (2020)
DOI 10.1128/mBio.02809-20
Co-authors Jay Horvat
2019 Keenan CR, Iannarella N, Garnham AL, Brown AC, Kim RY, Horvat JC, et al., 'Polycomb repressive complex 2 is a critics mediator of allergic inflammation', JCI INSIGHT, 4 (2019) [C1]
DOI 10.1172/jci.insight.127745
Citations Scopus - 13Web of Science - 13
Co-authors Jay Horvat
2017 Liu G, Cooley MA, Nair PM, Donovan C, Hsu AC, Jarnicki AG, et al., 'Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c', JOURNAL OF PATHOLOGY, 243 510-523 (2017) [C1]
DOI 10.1002/path.4979
Citations Scopus - 79Web of Science - 78
Co-authors Tattjhong Haw, Christopher Grainge, Jay Horvat, Chantal Donovan
2017 Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, et al., 'Role for NLRP3 inflammasome-mediated, IL-1ß-dependent responses in severe, steroid-resistant asthma', American Journal of Respiratory and Critical Care Medicine, 196 283-297 (2017) [C1]

Rationale: Severe, steroid-resistant asthma is the major unmet need in asthma therapy. Disease heterogeneity and poor understanding of pathogenic mechanisms hampers the identifica... [more]

Rationale: Severe, steroid-resistant asthma is the major unmet need in asthma therapy. Disease heterogeneity and poor understanding of pathogenic mechanisms hampers the identification of therapeutic targets. Excessive nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome and concomitant IL-1ß responses occur in chronic obstructive pulmonary disease, respiratory infections, and neutrophilic asthma. However, the direct contributions to pathogenesis, mechanisms involved, and potential for therapeutic targeting remain poorly understood, and are unknown in severe, steroid-resistant asthma. Objectives: To investigate the roles and therapeutic targeting of the NLRP3 inflammasome and IL-1ß in severe, steroid-resistant asthma. Methods: We developed mouse models of Chlamydia and Haemophilus respiratory infection-mediated, ovalbumin-induced severe, steroid-resistant allergic airway disease. These models share the hallmark features of human disease, including elevated airway neutrophils, and NLRP3 inflammasome and IL-1ß responses. The roles and potential for targeting of NLRP3 inflammasome, caspase-1, and IL-1ß responses in experimental severe, steroid-resistant asthma were examined using a highly selective NLRP3 inhibitor, MCC950; the specific caspase-1 inhibitor Ac-YVAD-cho; and neutralizing anti-IL-1ß antibody. Roles for IL-1ß-induced neutrophilic inflammation were examined using IL-1ß and anti-Ly6G. Measurements and Main Results: Chlamydia and Haemophilus infections increase NLRP3, caspase-1, IL-1ß responses that drive steroid-resistant neutrophilic inflammation and airway hyperresponsiveness. Neutrophilic airway inflammation, disease severity, and steroid resistance in human asthma correlate with NLRP3 and IL-1ß expression. Treatment with anti-IL-1ß, Ac- YVAD-cho, and MCC950 suppressed IL-1ß responses and the important steroid-resistant features of disease in mice, whereas IL-1ß administration recapitulated these features. Neutrophil depletion suppressed IL-1ß-induced steroid-resistant airway hyperresponsiveness. Conclusions: NLRP3 inflammasome responses drive experimental severe, steroid-resistant asthma and are potential therapeutic targets in this disease.

DOI 10.1164/rccm.201609-1830OC
Citations Scopus - 281Web of Science - 226
Co-authors Jay Horvat, Jemma Mayall, Jodie Simpson, Katherine Baines, Lisa Wood
2016 Simpson JL, Baines KJ, Horvat JC, Essilfie AT, Brown AC, Tooze M, et al., 'COPD is characterized by increased detection of Haemophilus influenzae, Streptococcus pneumoniae and a deficiency of Bacillus species', Respirology, 21 697-704 (2016) [C1]

Background and objective Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and inflammation. Airway bacterial colonization is increas... [more]

Background and objective Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and inflammation. Airway bacterial colonization is increased in COPD; however, the role of potentially pathogenic and non-pathogenic bacteria in the pathogenesis of disease is unclear. This study characterized the presence of bacteria in a well-characterized cohort of adults with COPD and healthy controls. Methods Adults with COPD (n = 70) and healthy controls (n = 51) underwent clinical assessment and sputum induction. Sputum was dispersed, and total and differential cell counts were performed. Bacteria were cultured, identified and enumerated. Supernatants were assessed for neutrophil elastase (NE) and IL-1ß. Common respiratory pathogens were also determined using real-time PCR. Results Participants with COPD had a typical neutrophilic inflammatory profile. The total load of bacteria was increased in COPD and was associated with poorer respiratory health status, as measured by the St George's Respiratory Questionnaire (Spearman's r = 0.336, P = 0.013). Significantly lower levels of culturable Bacillus species were identified compared with healthy controls. PCR analyses revealed increased rates of detection of potentially pathogenic bacteria with Haemophilus influenzae detection associated with higher sputum levels of NE and IL-1ß, while Streptococcus pneumoniae was more common in male ex-smokers with emphysema and a deficit in diffusion capacity. Conclusion Non-pathogenic and pathogenic bacteria were altered in the sputum of patients with COPD. These observations highlight the potential to identify treatment and management strategies that both target specific bacterial pathogens and restore the microbial balance, which may lead to reductions in inflammation and subsequent improvements in lung health.

DOI 10.1111/resp.12734
Citations Scopus - 47Web of Science - 42
Co-authors Katherine Baines, Jay Horvat, Vanessa Mcdonald, Jodie Simpson
2016 Gold MJ, Hiebert PR, Park HY, Stefanowicz D, Le A, Starkey MR, et al., 'Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization', Mucosal Immunology, 9 809-820 (2016) [C1]

Exposure to particulate matter (PM), a major component of air pollution, contributes to increased morbidity and mortality worldwide. PM induces innate immune responses and contrib... [more]

Exposure to particulate matter (PM), a major component of air pollution, contributes to increased morbidity and mortality worldwide. PM induces innate immune responses and contributes to allergic sensitization, although the mechanisms governing this process remain unclear. Lung mucosal uric acid has also been linked to allergic sensitization. The links among PM exposure, uric acid, and allergic sensitization remain unexplored. We therefore investigated the mechanisms behind PM-induced allergic sensitization in the context of lung mucosal uric acid. PM 10 and house dust mite exposure selectively induced lung mucosal uric acid production and secretion in vivo, which did not occur with other challenges (lipopolysaccharide, virus, bacteria, or inflammatory/fibrotic stimuli). PM 10 -induced uric acid mediates allergic sensitization and augments antigen-specific T-cell proliferation, which is inhibited by uricase. We then demonstrate that human airway epithelial cells secrete uric acid basally and after stimulation through a previously unidentified mucosal secretion system. Our work discovers a previously unknown mechanism of air pollution-induced, uric acid-mediated, allergic sensitization that may be important in the pathogenesis of asthma.

DOI 10.1038/mi.2015.104
Citations Scopus - 60Web of Science - 53
Co-authors Jay Horvat
2016 Starkey MR, Nguyen DH, Brown AC, Essilfie AT, Kim RY, Yagita H, et al., 'PD-L1 Promotes Early-life Chlamydia Respiratory Infection-induced Severe Allergic Airway Disease.', American journal of respiratory cell and molecular biology, (2016) [C1]
Citations Scopus - 19Web of Science - 15
Co-authors Jay Horvat
2013 Starkey MR, Nguyen DH, Kim RY, Nair PM, Brown AC, Essifie A-T, et al., 'Programming of the Lung in Early Life by Bacterial Infections Predisposes to Chronic Respiratory Disease', CLINICAL OBSTETRICS AND GYNECOLOGY, 56 566-576 (2013) [C1]
DOI 10.1097/GRF.0b013e3182993a0c
Citations Scopus - 14Web of Science - 13
Co-authors Jay Horvat
2013 Thorburn AN, Brown AC, Nair PM, Chevalier N, Foster PS, Gibson PG, Hansbro PM, 'Pneumococcal Components Induce Regulatory T Cells That Attenuate the Development of Allergic Airways Disease by Deviating and Suppressing the Immune Response to Allergen', JOURNAL OF IMMUNOLOGY, 191 4112-4120 (2013) [C1]
DOI 10.4049/jimmunol.1201232
Citations Scopus - 21Web of Science - 18
2013 Starkey MR, Jarnicki AG, Essilfie A-T, Gellatly SL, Kim RY, Brown AC, et al., 'Murine models of infectious exacerbations of airway inflammation', CURRENT OPINION IN PHARMACOLOGY, 13 337-344 (2013) [C1]
DOI 10.1016/j.coph.2013.03.005
Citations Scopus - 62Web of Science - 58
Co-authors Jay Horvat
Show 26 more journal articles

Conference (2 outputs)

Year Citation Altmetrics Link
2022 Mayall JR, Pillar AL, Daly K, Brown AC, Essilfie AT, Gomez HM, et al., 'Iron metabolism affects influenza A infection and associated disease.', Online (2022)
DOI 10.1111/resp.14226
Co-authors Jay Horvat, Jemma Mayall, Henry Gomez, Chantal Donovan
2021 Mayall JR, Hsu AC-Y, Horvat JC, Daly K, Chevalier A, Gomez HM, et al., 'Interferon-epsilon promotes susceptibility to influenza A and associated disease.', Online (2021)
DOI 10.1111/resp.14021
Co-authors Jay Horvat, Tattjhong Haw, Jemma Mayall, Henry Gomez
Edit

Grants and Funding

Summary

Number of grants 11
Total funding $2,942,510

Click on a grant title below to expand the full details for that specific grant.


20242 grants / $1,317,789

Manipulating iron metabolism in the airway mucosa for the treatment of severe asthma and COPD$1,299,359

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Jay Horvat, Doctor Alexandra Brown, Ama Essilfie, Dr Ama-Tawiah Essilfie, Associate Professor David Reid, Professor Jodie Simpson
Scheme Ideas Grants
Role Investigator
Funding Start 2024
Funding Finish 2026
GNo G2300370
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

Investigating the effect of feminizing, gender affirming hormone therapies on respiratory outcomes$18,430

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Doctor Alexandra Brown, Miss Olivia Carroll, Professor Jay Horvat, Doctor Katie Wynne
Scheme John Hunter Hospital Charitable Trust Grant
Role Lead
Funding Start 2024
Funding Finish 2025
GNo G2400685
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

20232 grants / $1,521,715

Personalising the management of obesity-associated asthma using medical nutrition therapy and physical activity prescription: The IDEAL Study$1,506,948

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Doctor Hayley Scott, Professor Lisa Wood, Doctor Sarah Valkenborghs, Professor Anne Dixon, Professor Jay Horvat, Doctor Natasha Weaver, Dr Serene Yoong, Doctor Bronwyn Berthon, Doctor Evan Williams, Doctor Alexandra Brown, Dr Sze Yoong
Scheme MRFF - PPHRI - Chronic Respiratory Conditions
Role Investigator
Funding Start 2023
Funding Finish 2024
GNo G2200660
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

Investigating how excess nutrients in obesity affect immune responses to respiratory virus infection$14,767

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Doctor Lily Williams, Doctor Alexandra Brown, Doctor Alexandra Brown, Professor Jay Horvat, Doctor Evan Williams, Doctor Geoffrey Tyler
Scheme John Hunter Hospital Charitable Trust Grant
Role Investigator
Funding Start 2023
Funding Finish 2023
GNo G2300690
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

20221 grants / $11,289

Treatment with a hepcidin mimetic to regulate iron levels in respiratory diseases such as asthma, COPD$11,289

Funding body: Protagonist Therapeutics Inc

Funding body Protagonist Therapeutics Inc
Project Team Professor Jay Horvat, Doctor Alexandra Brown
Scheme Research Grant
Role Investigator
Funding Start 2022
Funding Finish 2022
GNo G2200942
Type Of Funding C3400 – International For Profit
Category 3400
UON Y

20213 grants / $27,994

Investigating the role of sex hormones in obesity associated susceptibility to respiratory viral disease$18,182

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Doctor Evan Williams, Doctor Alexandra Brown, Professor Jay Horvat, Doctor Bronwyn Berthon, Doctor David Arnold
Scheme John Hunter Hospital Charitable Trust Grant
Role Investigator
Funding Start 2021
Funding Finish 2021
GNo G2100212
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

Investigating the therapeutic potential of targeting iron in IPF$5,000

Funding body: Lung Foundation Australia

Funding body Lung Foundation Australia
Project Team Doctor Alexandra Brown, Professor Jay Horvat
Scheme Research Grant
Role Lead
Funding Start 2021
Funding Finish 2021
GNo G2100949
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

Investigating the role of sex hormones in obesity associated susceptibility to respiratory viral disease$4,812

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Alexandra Brown
Scheme Research Grant
Role Lead
Funding Start 2021
Funding Finish 2021
GNo G2100151
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20201 grants / $12,162

Investigating the role of sex hormones in in obese and non-obese asthmatic females$12,162

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Evan Williams, Doctor Alexandra Brown, Professor Lisa Wood, Professor Jay Horvat, Doctor David Arnold, Doctor Bronwyn Berthon
Scheme Research Grant
Role Investigator
Funding Start 2020
Funding Finish 2020
GNo G2000392
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

20191 grants / $25,000

The role and therapeutic manipulation of female sex hormones in asthma$25,000

Funding body: Priority Research Centre (PRC) for Healthy Lungs | The University of Newcastle

Funding body Priority Research Centre (PRC) for Healthy Lungs | The University of Newcastle
Project Team

Alexandra Brown, Jemma Mayall, Hayley Scott, Katie Wynne, Jay Horvat, Lisa Wood

Scheme Integration Grant
Role Lead
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

20121 grants / $26,561

Mechanisms of predisposition to secondary bacterial pneumonia$26,561

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Alexandra Brown
Scheme Research Higher Degree Support Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1201160
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y
Edit

Research Supervision

Number of supervisions

Completed1
Current4

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2023 PhD Understanding How Obesity And Nutrient Excess Promotes Severe Lung Disease. PhD (Nutritional Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2023 PhD Investigating The Gut - Lung Axis In Respiratory Infections In Inflammatory Bowel Disease PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2021 PhD Investigation and Therapeutic Manipulation of Iron Uptake Responses in Respiratory Disease PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2020 PhD Investigating the Role and Therapeutic Manipulation of Female Sex Hormones in Asthma PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2021 PhD Mechanisms and Therapeutic Targeting of Immunometabolism in Lung Disease PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
Edit

Dr Alexandra Brown

Position

Post Doctorate Researcher
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Contact Details

Email alexandra.brown@newcastle.edu.au
Phone (02) 4042 0201

Office

Room Level 2 East
Building HMRI
Location New Lambton Heights

,
Edit